This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
All content for MedEdicus Podcasts is the property of MedEdicus and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
(CME Podcast) Improving Outcomes in Patients With Geographic Atrophy: Cases in Clinical Practice - Part 1
MedEdicus Podcasts
29 minutes
8 months ago
(CME Podcast) Improving Outcomes in Patients With Geographic Atrophy: Cases in Clinical Practice - Part 1
Geographic atrophy is a growing healthcare concern for retina specialists caring for an aging population. In the first part of this podcast series titled, Improving Outcomes in Patients with Geographic Atrophy, our experts, Dr. Arshad Khanani and Dr. Lejla Vajzovic, will educate listeners on the disease epidemiology, pathophysiology, and relevant clinical features of GA on imaging. The discussion will include didactics presented by our experts and real-world case studies.
MedEdicus Podcasts
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
